All Regeneron articles
-
BusinessUS supreme court confirms Amgen’s cholesterol antibody patents invalid
Decision could mean patent descriptions need to be even more detailed, and hence expensive
-
BusinessRegeneron’s Covid-19 antibodies help those who can’t make their own
Regn-Cov2 reduces deaths and shortens hospitalisation for these patients, even when given at late stages of infection
-
BusinessCoronavirus variants stymie success of monoclonal antibodies
Lab-made antibodies can treat and protect people from Covid-19 but are more likely to succeed when administered as a cocktail
-
BusinessCholesterol drug withdrawn in patent dispute
Ruling that Regeneron’s Praluent antibody infringes Amgen’s Repatha patent could stifle innovation
-
Business
Grabbing slices of the immuno-oncology pie
Another spate of immuno-oncology dealmaking adds to fervour in pharma’s ‘hottest space’
-
News
Regeneron expands, creating 400 new jobs
US biotech firm announces second expansion in six months